



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

- (15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**INID code(s) 73**
- (51) Int Cl.:  
**C12N 15/11** <sup>(1990.01)</sup> **A61K 31/7088** <sup>(2000.01)</sup>  
**A61P 35/00** <sup>(2000.01)</sup> **A61P 35/04** <sup>(2000.01)</sup>
- (48) Corrigendum issued on:  
**18.01.2006 Bulletin 2006/03**
- (86) International application number:  
**PCT/CA2000/000120**
- (45) Date of publication and mention  
of the grant of the patent:  
**09.11.2005 Bulletin 2005/45**
- (87) International publication number:  
**WO 2000/047733 (17.08.2000 Gazette 2000/33)**
- (21) Application number: **00903456.2**
- (22) Date of filing: **09.02.2000**

(54) **ANTITUMOR ANTISENSE SEQUENCES DIRECTED AGAINST R1 AND R2 COMPONENTS OF RIBONUCLEOTIDE REDUCTASE**

ANTITUMOR-ANTISENSE SEQUENZEN GEGEN DIE R1 UND R2 KOMPONENTEN DER RIBONUKLEOTIDREDUKTASE

SEQUENCES ANTISENS ANTITUMORALES CONTRE LES CONSTITUANTS R1 ET R2 DE LA RIBONUCLEOTIDE REDUCTASE

- |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>(84) Designated Contracting States:<br/><b>AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE</b><br/>Designated Extension States:<br/><b>AL LT LV MK RO SI</b></p> <p>(30) Priority: <b>11.02.1999 US 249730</b></p> <p>(43) Date of publication of application:<br/><b>14.11.2001 Bulletin 2001/46</b></p> <p>(73) Proprietor: <b>GeneSense Technologies Inc.</b><br/><b>Toronto, Ontario M9W 4Z7 (CA)</b></p> <p>(72) Inventors:<br/>• <b>WRIGHT, Jim, A.</b><br/><b>Aurora, Ontario L4G 3V4 (CA)</b><br/>• <b>YOUNG, Aiping H.</b><br/><b>North York, Ontario M2R 1P3 (CA)</b></p> <p>(74) Representative: <b>Maschio, Antonio</b><br/><b>D Young &amp; Co</b><br/><b>120 Holborn</b><br/><b>London EC1N 2DY (GB)</b></p> <p>(56) References cited:<br/><b>WO-A-98/05769</b></p> | <ul style="list-style-type: none"><li>• <b>HUANG AIPING ET AL: "Ribonucleotide reductase R2 gene expression and changes in drug sensitivity and genome stability." CANCER RESEARCH, vol. 57, no. 21, 1 November 1997 (1997-11-01), pages 4876-4881, XP002053166 ISSN: 0008-5472</b></li><li>• <b>MADER ROBERT M ET AL: "Transcription and activity of 5-fluorouracil converting enzymes in fluoropyrimidine resistance in colon cancer in vitro." BIOCHEMICAL PHARMACOLOGY, vol. 54, no. 11, 1 December 1997 (1997-12-01), pages 1233-1242, XP002053167 ISSN: 0006-2952</b></li><li>• <b>FAN HUIZHOU ET AL: "The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 94, no. 24, 25 November 1997 (1997-11-25), pages 13181-13186, XP002137570 ISSN: 0027-8424</b></li></ul> |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- ANAZODO M ET AL: "Relative levels of inhibition of p24 gene exüression by different 20-mer antisense oligonucleotid sequences targeting nucleotides +1129 to +1268 of the HIV1 gag genome: an analysis of mechanism" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 229, 1996, pages 305-309, XP002089438 ISSN: 0006-291X cited in the application